A Multicenter Phase I/II Trial of Anastrozole Palbociclib Trastuzumab and Pertuzumab in HR-positive Her2-positive Metastatic Breast Cancer (ASPIRE)

Brief description of study

The purpose of this study is to assess the safety and effectiveness of giving anastrozole, palbociclib, trastuzumab and pertuzumab to women with hormone receptor (HR)-positive, HER2-positive metastatic breast cancer. This combination of medications represents an all biologic approach and avoids chemotherapy as first line treatment of this disease. You may qualify to take part in this research study because you have metastatic (spread to other parts of your body) breast cancer that is dependent on HER2neu (a protein), estrogen (a hormone) and/ or progesterone (a hormone). Palbociclib, anastrozole, pertuzumab and trastuzumab are approved for treatment of metastatic breast cancer. Funds for conducting this research are provided by Pfizer, which is the manufacturer of palbociclib.


Clinical Study Identifier: s17-01825
ClinicalTrials.gov Identifier: NCT03304080
Principal Investigator: Maryann J Kwa.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.